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2. ABBREVIATIONS 
 
ABC  Avidin-biotin-complex 
AEC  3-amino-9-ethylcarbazole 
AIF  Apoptosis inducing factor 
Akt  Proteine kinase Akt 
AP-1  Activator protein 1 
APAF-1 Apoptosis protease activationg factor-1 
APC  Adenomatous polyposis coli 
ARF  Alternative reading frame 
ATF1 and 2 Activating transcription factor 1 and 2 
Bak  Bcl-2 antagonist killer 
Bax  Bcl-2-associated X protein 
Bcl-2  B-cell leukemia/lymphoma-2 
Bid  BH3 interacting domain death agonist 
Bim  Bcl-2 like 11 
B-RAF V-raf murine sarcoma viral oncogene homolog B1 
cAMP  Cyclic adenosine monophosphate 
CDK  Cyclin dependent kinase 
CDKI  Cyclin dependent kinase inhibitor 
CDKN2A Cyclin dependent kinase inhibitor 2A 
c-fos  Cellular fos proto-oncogene 
c-jun  Cellular jun proto-oncogene 
c-myc  Cellular myc proto-oncogene 
CREB  cAMP responsive element binding protein 
DAB  Diaminobenzidine tetrahydrocloride 
DISC  Death-inducing signal complex 
DNA  Deoxyribonucleic acid 
DPC4  Deleted in pancreatic cancer, locus 4/SMAD family member 4 
E2F  E2F transcription factor 
ECM  Extracellular matrix 
EGF   Epidermal growth factor  
 7
EGR1  Early growth response 1 
EGFR   Epidermal growth factor receptor 
Elk1  ELK1, member of ETS oncogene family 
ERK  Extracellular signal-regulated kinases  
Ets1  v-ets erythroblastosis virus E26 oncogene homolog 1 
FABP  Fatty acid binding protein 
FAK  Focal adhesion kinase 
FADD  Fas-associated death domain protein 
Fas  TNF receptor superfamily, member 6 
FasL  Fas lignad 
FGFR   Fibroblast growth factor receptor 
GSK3- Glycogen synthase kinase-3 beta 
IAP  Inhibitor of apoptosis 
ICAT  beta-catenin-interacting protein 
ILK  Integrin-linked kinase 
INK4  Inhibitor of cyclin dependent kinase 4 
JNK  c-jun N-terminal kinase 
kDa  kilo dalton 
KIT  v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
LEF1  Lymphoid enhancer binding factor-1 
MAPK  Mitogen activated protein kinase 
Mcl-1  Myeloid cell leukemia sequence 1 
MDM2 Mouse double minute 2 
MEF2A Myocyte enhancer factor 2A 
MITF  Microphtalmia-associated transcriptional factor 
MMP  matrix metalloproteinase 
MNK1/2 MAPK interacting serine/threonine kinase 1 and 2 
mRNA  Messenger ribonucleic acid 
mTOR  Mammalian target of rapamycin 
NFAT4 Nuclear factor of activated T-cells 4 
NF-B  Nuclear factor kappa-B 
NGF  Nerve growth factor 
H-RAS Human homolog to Harvey rat viral sarcoma oncogene, encoding RAS 
N-RAS Neuroblastoma RAS viral (v-ras) oncogene homolog 
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PDGFR  Platelet-derived growth factor receptor  
PDK1 and 2 Phosphoinositide–(3,4,5)-triphosphate-dependent-kinases 1and 2 
PI3K  Phosphoinositide 3 kinase 
PIP2  Phosphatidylinositol-4,5-bisphosphate 
PIP3  Phosphatidylinositol-3,4,5-trisphosphate 
PKC  Protein kinase C 
PLA2  Phospholipase A2 
PMA  Phorbol-12-myristate-13-acetate 
PP2  4-Amino-5-(4-chlorphenyl)-7-(t-butyl)(3,4-d) pyrimidine 
PPAR  peroxisome proliferators-activated receptor 
PTEN  Phosphatase and tensin homolog deleted from chromosome 10 
RACK1 Receptor for activated kinase C 1 
RB  Retionoblastoma 
RTK  Receptor tyrosine kinase 
RGF  Radial growth phase 
SA--GAL Senescence associated acidic -galactosidase 
Sap-1a  Serum response factor (SRF) associated protein 1 
Shc  Src homology 2 domain containing 
siRNA  Small interfering RNA 
Smac/Diablo Second mitochondria-derived activator of caspases/Direct IAP-binding 
protein 
SMAD4 Mothers against decapentaplegic homolog 4 
Src  Human homolog to the avian v-Src gene of the Rous Sarcoma virus 
STAT1/3 Signal transducer and activator of transcription 1 and 3 
Tau  Microtubule-associated protein Tau 
TPA  12-O-tetradecanoyl phorbol 13-acetate 
TRAIL TNF-related apoptosis-inducing ligand 
TUNEL Terminal deoxynucleotidyl transferase end labeling 
UV  Ultra violet 
VEGFR  Vascular endothelian growth factor receptor 
VGF  Vertical growth phase 
Wnt  Wingless-type MMTV integration site family 
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3. AIMS OF THE STUDY 
 
Malignant melanoma is a severe cancer form, and the death risk among patients with an 
advanced stage of this cancer is high. So far, cancer therapy has had little effect on 
survival, and the need for identifying factors involved in development and progression 
of malignant melanoma is urgent. Mapping of cell signaling mechanismes involved in 
oncogenesis is of importance, and relevant signaling pathways may be potential targets 
for treatment. 
 
The aims of this thesis were; 
 
I. To investigate the expression of MAP kinases in malignant melanoma 
specimens, and analyze the relationship to clinicopathological parameters 
and patient survival. 
 
II. To study the regulation of the ERK1/2 pathway by PKC and elucidate the 
molecular mechanisms responsible for this regulation  
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5. GENERAL INTRODUCTION 
 
5. 1. Cancer 
 
Homeostasis, the finely tuned balance between cell proliferation and cell death, is 
essential for maintaining the organism. When homeostasis is disturbed, either by 
increased cell proliferation or by a decrease in cell death, a neoplasm (neoplasm = new 
growth) may develop (1). In order to maintain homeostasis, genes that positively and 
negatively regulate cell growth and proliferation are required, and these genes are called 
proto-oncogenes and tumor suppressor genes, respectively (2). Moreover, series of 
repair genes contributes to keeping genetic alterations to a minimum. Molecular changes 
in several of these genes at the same time may give growth advantages to the cell and 
eventually lead to cancer development and progression (3).  
 
The development of cancer is a multi-step process. One of the hallmarks is increased 
cell proliferation. Cancer cells eventually become self-sufficient with growth signals, 
allowing the cells to proliferate in absence of mitotic signals. Tumor cells are also 
insensitive to anti-growth signals, are able to avoid apoptosis, and have limitless 
replicative potential. Together, these events contribute to increased cell proliferation. 
Sustained angiogenesis, the formation of new blood vessels from pre-existing blood 
vessels, is another cancer hallmark. Blood vessels supply tissue with nutrients and 
oxygen, and all cells in the body reside close to a capillary blood vessel. During cancer 
progression, tumor cells move out from their origin and invade adjacent tissue where 
blood and lymph vessels allow them to travel to distant sites where they establish a 
metastasis (Figure 1.) (4). 
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Figure 1. The main steps in the metastatic process. Reprinted by permission from Macmillan Publishers  
Ltd : ref. (5), © 2003 . 
  
5.2. Cell cycle regulation 
 
In order to divide, cells go through a cycle divided into four phases, G1, S, G2 and M. 
The periods associated with DNA synthesis (S-phase) and mitosis (M-phase) are 
separated by gaps of varying length, G1 and G2. However, most cells pause in their 
progress around the cell cycle, and rest in a state called G0 (6). Progression through the 
G1 phase is highly dependent on extra-cellular mitotic stimuli, like growth factors, 
stimulating the cells to overcome the so-called restriction point in late G1 phase. Two 
main cell cycle checkpoints control the order and timing of cell cycle transitions (G1–S 
and G2–M) and ensure that critical events such as DNA replication and chromosome 
segregation are completed correctly before allowing the cells to progress further through 
the cycle (7-9). After the G1 restriction point, the cells can complete their cycle 
independently of external stimuli (6). Progression through the cell cycle is driven by the 
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actions of cyclin dependent kinases (CDKs) and their activating cyclin subunits (Figure 
2). CDK-cyclin complexes phosphorylate and inactivate the retinoblastoma protein, 
pRb, which then releases the E2F transcription factor, allowing the cells to express 
genes essential for cell cycle progression (10).  
CDK activity is suppressed through interactions with two main families of inhibitory 
proteins (CDK inhibitors or CDKIs); The INK4 family and the CIP/KIP family. The 
INK4 family includes p16INK4a, p15INK4b, p18INK4c, and p19INK4d (ARF) and specifically 
binds and inhibits CDK4 and CDK6.  p19ARF shares two exons with p16INK4a as a result 
of a spliced CDKN2A gene and is also known as an activator of p53 through blocking of 
the function of MDM2 (11). The Cip/Kip family comprises p21Cip1/WAF1, p27Kip1, and 
p57Kip2.  The Cip/Kip proteins act as negative regulators of cyclin E/A-Cdk2 complexes 
and the cyclin B-Cdk1 complex as well as positive regulators of cyclin D-Cdk4/6 
complexes (12).  
 
 
 
 
Figure 2. The cell cycle. Reprinted by permission from Macmillan Publishers Ltd.: ref. (13), © (2007)  
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5.3. Apoptosis 
 
 The process of self-destruction of cells that are genetically programmed to have a 
limited life span or are damaged is called apoptosis (14). The mechanisms of 
programmed cell death are of great importance, being involved in development, 
differentiation, proliferation, homeostasis, regulation and function of the immune system 
and in the removal of defective cells (15). The morphological characteristics of 
apoptosis are chromatin condensation (pyknosis), nuclear fragmentation, plasma 
membrane blebbing and cell shrinkage (16). Apoptosis can be induced either by a 
stimulus, such as irradiation or toxic drugs, or by removal of a repressor agent, leading 
the cells to disintegrate into membrane-bound particles that are eliminated by 
phagocytosis (17).  
 
The major executors of the apoptotic machinery are the caspases, a family of cysteine-
dependent aspartate-specific proteases that cleaves substrates after aspartic acid (asp) 
residues (18). The caspases are divided into the initiator caspases (caspase-2, -8, -9 and 
10) and effector caspases (caspase-3, -6, and -7) and they are activated through either an 
extrinsic or an intrinsic pathway (Figure 3).  
 
The extrinsic pathway is initiated through stimulation of transmembrane death receptors 
by ligands such as Fas, TNF- and TRAIL (19). For example, binding of FasL to Fas 
receptors on the target cell will trigger the aggregation of multiple receptors on the 
surface. Following this aggregation, an adaptor protein known as Fas-associated death 
domain protein (FADD) is recruited in the cytoplasm. FADD, in turn, activates caspase-
8 to form the death-inducing signal complex (DISC). Through the recruitment of 
caspase-8 to DISC, caspase-8 will be activated and then directly activate caspase-3 to 
initiate degradation of the cell. Active caspase-8 can also cleave the Bid protein to tBid, 
which acts as a signal on the membrane of mitochondria to facilitate the release of 
cytochrome c in the intrinsic pathway (20).   
The intrinsic pathway, also referred to as the mitochondrial pathway, is initiated through 
the release of signaling factors by mitochondria within the cell (17).  The intrinsic 
pathway is triggered by cellular stress, specifically mitochondrial stress caused by 
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factors such as DNA damage and heat shock (21), leading to a permeability change in 
the mithocondrial membrane. The pro-apoptotic proteins, Bax and Bid, residing in the 
cytoplasm, as well as Bak within the mitochondria, are now allowed to promote the 
release of cytochrome c from the mitochondria and into the cytosol. Following this 
release, cytochrome c forms a complex in the cytoplasm with ATP and Apaf-1, which 
will activate caspase-9. Activated caspase-9 will together with the complex of 
cytochrome c, ATP and Apaf-1 form an apoptosome, which in turn activates caspase-3, 
the effector protein that initiates degradation. In addition to cytochrome c, the released 
intramembrane content also contains apoptosis inducing factor (AIF) to facilitate DNA 
fragmentation, and Smac/DIABLO proteins to inhibit inhibitor of apoptosis (IAP) 
proteins (22). 
 
 
Figure 3. The intrinsic and extrinsic pathways leading to apoptosis. Reprinted by permission from 
The Science Creative Quarterly.  
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5.3.1. Anoikis 
Adhesion to extracellular matrix (ECM) is essential for survival of most normal cells, 
and loss of adhesion induces a special form of anchorage-deprived apoptosis termed 
“anoikis”, a Greek word for homelessness (23).  Anoikis is of great importance in vivo, 
because disruption of this life-and death control enhances  tumor metastasis, allowing 
cells to survive in totally inappropriate ECM environments (24). Adhesion of cells to 
ECM is mainly mediated by integrins. These are transmembrane cell surface 
heterodimers composed of an -chain and a -chain. In mammals, 18 -subunits and 8 
-subunits have been identified, which can combine into 24 different heterodimers, each 
with specific recognition and affinities for various ECM components and other adhesion 
molecules (25). Integrins mediate their signals via integrin-associated non-receptor 
kinases such as focal adhesion kinase (FAK), integrin-linked kinase (ILK) and Shc, 
leading to activation of the PI3K, MAPK/ERK1/2 and JNK pathways (25;26). Over-
expression of FAK and ILK has been shown to inhibit anoikis in vitro (27;28). During 
anoikis, cells undergo the same phenotypic changes as an apoptotic cell. 
 A number of studies have implicated members of the Bcl-2 family in playing important 
roles in anoikis (23). Depending on cell type, anoikis has been accompanied by changes 
in protein expression levels or phosphorylation/activation status in the pro-apoptotic 
proteins Bad, Bax and Bak, as well as in the anti-apoptotic protein Mcl-1 (29-31). 
Moreover, the pro-apoptotic protein Bim has been shown to promote anoikis in 
epithelial cells (32).  
 
5.3.2 Entosis 
In the absence of apoptosis/anoikis, cells still manage to convert into a necrotic state, but 
the roles of necrosis as well as other possible mechanisms for cell elimination in cancer 
development are poorly understood. In 2007, Overholtzer et al. (33) described a new 
mode of non-apoptotic cell elimination called “entosis” (a greek word for “within”). In 
short, this mechanism, that resembles cell cannibalism, is provoked by loss of 
attachment to matrix. A single, live cell invades another live cell, and will during its 
internalization be degraded by lysosomal enzymes. This death process does not involve 
apoptotic signals and is therefore distinct from the phagocytic ingestion of dying cells 
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observed during apoptosis. Moreover, not all internalized cells are degraded. A small 
percentage actually divides within the host cell and is eventually released. The invasion 
of cells is carried out through signaling via the small GTPase Rho, which mediates 
actomyosin-mediated contraction. Before invasion, the two cells establish E-cadherin--
catenin-mediated adherens junctions, whose compaction appears to directly mediate the 
entosis process. This cell-in-cell phenotype is associated with human tumors, and it has 
been suggested that entosis functions as a tumor suppressing mechanism which 
eliminates detached cells.  
 
5.4. Signaling pathways 
 
The cellular homeostasis is under control of different protein kinases that can transduce 
signals from extracellular matrix (ECM) to the nucleus where gene expression is 
triggered. The most prominent signal transduction pathways in this regard are the 
mitogen-activated protein kinase (MAPK) cascades and the phosphatidylinositol-3 
kinase (PI3K)/Akt signaling pathway. 
 
5.4.1. The MAPK pathways 
 
The MAPKs comprise a family of protein serine-threonine kinases which, depending on 
the context, have been correlated to different responses like proliferation, cell growth, 
differentiation and cell survival (34). In mammalian cells, three major MAPK families 
have been characterized; the extracellular signal-regulated kinases 1 and 2 (ERK1/2), C-
jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 kinase. Each 
of these cascades consists of three enzymes that are activated in series: a MAPK kinase 
kinase (MAPKKK or MEKK), a MAPK kinase (MAPKK or MEK) and a MAP kinase 
(MAPK). At least 14 MAPKKKs, 7 MEKs and 12 MAPKs have been identified in 
mammalian cells (35).  
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5.4.1.1. RAFs 
 
The receptor tyrosine kinase effector RAF (Rapidly Accelerated Fibrosarcoma) belongs 
to a family of serine/threonine protein kinases. There are three mammalian RAF 
isoforms identified; A-RAF B-RAF and C-RAF/RAF-1, all translated from distinct 
genes on different chromosomes and expressed in various tissues (36;37). RAF plays an 
important role in tumorigenesis, both as a signal transducer from its upstream mediators, 
but also as an oncogene itself. Both A-RAF and C-RAF requires two mutated spots for 
oncogenic transformation, thus, oncogenic mutations in human cancers are rare. 
However, B-RAF requires only one mutational event, and activating mutations in B-
RAF have been observed in many human cancers like malignant melanoma, ovarian 
cancer, colorectal cancer and non-small-cell lung cancer (36). The most common 
mutation in B-RAF is a valine to glutamic acid substitution at residue 600 which is 
followed by constitutive activation of the MEK-ERK1/2 pathway (38). In addition to its 
high mutational frequency, B-RAF is also the isoform with the highest basal kinase 
activity as well as the one that interacts best with its upstream mediator, RAS (36). 
 
5.4.1.2. The ERK1/2 pathway 
 
The best characterized MAPK signaling pathway is the one that proceeds through the 
extracellular signal-regulated kinases 1 and 2 (ERK1/2). ERK1 and ERK 2 have the size 
of 44 kDa and 42 kDa, respectively, and share 83 % homology, but most of the 
differences reside outside their kinase core (39;40). Several experiments suggest that 
ERK1 and ERK2 are functionally equivalent, and the two ERK isoforms are usually co-
expressed (39). ERK1/2 is expressed in all tissue, and upon activation ERK1/2 plays a 
central role in several processes, including proliferation, differentiation and 
development, as well as cell survival, migration, apoptosis, morphology determination 
and oncogenic transformation (41). The ERK1/2 signaling cascade is initiated by 
extracellular signals, such as growth factors or hormones, that bind to a receptor tyrosine 
kinase (RTK) in the cell membrane which then activates the GTP-bound protein, RAS. 
A variety of RTKs interacts with RAS, including the epidermal growth factor receptor 
(EGFR), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), 
platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor 
receptor (VEGFR) and fibroblast growth factor receptor (FGFR). Activated RAS will in 
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turn activate the first MAPKKK (RAF), which again phosphorylates and activates 
MEK1/2. ERK1/2 is then subsequently activated by dual phosphorylation of MEK1/2 
(40-42).  Following ERK1/2 phosphorylation, its downstream cytoplasmic targets 
pp90RSK, EGFR, RAF-1, STAT1/3 and MEK1/2 are phosphorylated (43-46), and 
following translocation to the nucleus, ERK1/2 phosphorylates and activates 
transcription factors such as c-jun, c-myc (47), elk1/p62TCF (48) and RNA polymerase 
II (49) (Figure 4).  
 
MEK1 and MEK2 are activated by phosphorylation of two serine/threonine residues, 
each partially increasing the activity of MEK1/2 (42;50). However, the activity is 
regulated by additional phosphorylation/dephosphorylation processes as well. Activated 
ERK1/2, for instance, will be able to phosphorylate MEK1 at specific threonine 
residues, thereby leading to a negative feedback control on the ERK1/2 signaling 
cascade (41). The ERK1/2 signaling cascade plays an important role in cell cycle 
progression by inducing transcription of the cyclin D1 gene (51). On the other hand, 
recent evidence suggest a role for the ERK1/2 pathway in senescence and growth arrest, 
indicating a tumor suppressive effect as well (52). The ability of ERK1/2 to cause 
different and even opposing effects in the same cells has been questioned. Several 
studies have reported different effects based on the strength and duration of ERK1/2 
activation. In the first model described, PC12 cells were stimulated with epidermal 
growth factor (EGF) and nerve growth factor (NGF), known to promote proliferation 
and differentiation, respectively. It was shown that while EGF caused strong, transient, 
activation of ERK1/2, NGF caused strong, sustained activation of ERK1/2. Interestingly, 
it was also shown that artificially prolonged ERK1/2 activity induced differentiation 
instead of proliferation in the same cells. Moreover, it has been demonstrated that 
ERK1/2 signal duration is likely to influence the transcription and activity of immediate 
early genes, such as the transcription factors c-fos, c-jun, c-myc and EGR1 (41).  
 
ERK1/2 is an important component in oncogenesis. Increased ERK1/2 activity, 
associated with disease, has been demonstrated in prostate, breast, pancreatic and lung 
cancers (52), and constitutive activation of ERK1/2 has been shown to be present in 
malignant melanoma (53;54). Thus, this signaling pathway represents a major target for 
cancer therapy. 
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5.4.1.3. The SAPK/JNK and p38 pathways 
 
SAPK/JNK and p38 are called stress-activated protein kinases and are activated by 
cellular stress (eg, UV irradiation, osmotic stress, heat shock, protein synthesis 
inhibitors), inflammatory cytokines (eg, tumor necrosis factor- (TNF-) and 
interleukin-1) and G-protein coupled agonists (eg, thrombin). Like ERK1/2, both JNK 
and p38 are dually phosphorylated on tyrosine and threonine residues by MAPKKs. 
JNK is selectively phosphorylated by MKK4 and MKK7 and p38 is phosphorylated by 
MKK3 and MKK6 (34) (Figure 4). 
 
JNK and p38 regulate the expression of a number of cytokines, transcription factors and 
cell cycle regulators. The major outcome of JNK activation is phosphorylation of the c-
jun transcription factor, which upon activation leads to increased expression of genes 
with AP-1 (Activator protein-1) sites in their promoters (55). Other JNK targets include 
the transcription factors ATF2, Elk1,c-myc, p53, DPC4, Sap1a and NFAT4, all positive 
regulators of the transcription factor c-fos, further increasing the AP-1 level (51;56). On 
the other hand, activation of p38 is followed by phosphorylation of phospholipase A2, 
the microtubule-associated protein Tau, ATF1 and -2, MEF2A, Sap1, Elk1, NF-B, 
Ets1, and p53 amongst others (57) (Figure 4).  
 
Constitutive activation of the MAPK cascades has been observed in various in vitro 
tumor cell lines (58;59) and has been associated with carcinogenesis and metastatic 
potential of human cancers (60;61). Until recently it has been anticipated that the 
MAPK/ERK1/2 signaling pathway is involved in cell proliferation and survival because 
of its response to mitotic signals and proliferative cytokines, whereas activated JNK and 
p38 have been suggested to act as pro-apoptotic tumor suppressors in response to stress- 
mediated signals. Recent discoveries have, however, revealed that several MAPKs can 
phosphorylate the same substrates and also affect each other through cross-talk reactions 
and feedback mechanisms (52). For instance, several studies have demonstrated that 
MAPKKKs, believed to be specific for the JNK and p38 signaling pathway, directly 
phosphorylate the ERK1/2 specific MEK1/2 (62) (Figure 4). 
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Figure 4.  Major MAPK signaling cascades in mammalian cells. Adapted from (51). 
 
 
5.4.1.4. The PI3K pathway 
 
Phosphoinositide 3-kinases (PI3Ks) generate specific inositol lipids that have been 
implicated in regulation of cell growth, proliferation, survival, differentiation and 
cytoskeletal changes (63). The PI3K family is divided into three classes (I, II and III), 
but only class I PI3Ks are coupled to external stimuli and involved in oncogenesis 
(63;64). Class I PI3Ks are further classified into two functionally and structurally 
different subgroups, 1A and 1B, which transmit signals from receptor tyrosine kinases 
(RTK) and G-protein coupled receptors, like RAS, respectively (63). PI3K catalyzes 
phosphorylation of inositol-containing lipids, known as phosphatidylinositols (PtdIns) 
(65). The primary substrate of PI3K in vivo is phosphatidylinositol-4,5-bisphosphate 
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(PIP2) which is converted to phosphatidylinositol-3,4,5-triphosphate (PIP3) by 
phosphorylation (66). 
 
The mechanism by which PI3K promotes cell survival involves downstream activation 
of the protein kinase Akt (PKB). PIP2 and PIP3 lipids produced by PI3K are able to 
bind Akt, recruiting Akt to the plasma membrane where the phosphoinositide–(3,4,5)-
triphosphate-dependent-kinases, PDK1 and PDK2,  phosphorylate it to its active form. 
Activation of Akt promotes multiple effects on cell cycle regulation through 
phosphorylation and inactivation of the two cell cycle regulators, p27KIP1 and 
p21Cip1/WAF1. Akt activation also prevents degradation of cyclin D1 by inactivation of 
glycogen synthase kinase 3 (GSK-3) (67-69). Moreover, activated Akt targets 
proteins involved in cell death, including members of the Bcl-2 family and caspase-9, 
protecting cells from apoptosis. In addition, PI3K activation is able to increase the 
expression of members of the Inhibitors of Apoptosis family such as the c-IAPs (70). 
 
 
 
Figure 5. The PI3-kinase/Akt pathway. Reprinted by permission from Macmillan Publishers Ltd : ref. 
(66),  © (2002). 
 
 
The PI3K pathway is regulated by the tumor suppressor protein PTEN (Phosphatase and 
tensin homologue deleted on chromosome 10), which dephosphorylates PIP3 (71).  
Inactivation of PTEN due to mutation or deletion leads to increased activation of Akt 
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and thereby amplified effect of PI3K signalling (72). Several components of the PI3K 
pathway, such as Akt and mTor, are often deregulated in cancer, making this pathway an 
important therapeutic target (66).  
 
In a simplified version, the ERK1/2 pathway and the PI3K pathway act in parallel to 
promote survival. However, cross-talk between the two pathways has been demonstrated 
in several cell lines.  The balance between ERK1/2 signalling and PI3K signalling 
depends on the nature of the agonist and the cellular background (73-75).  
 
5.4.1.5. PKC 
 
The protein kinase C (PKC) family is a family of serine/threonine kinases that plays key 
regulatory roles in a variety of cellular processes, such as proliferation, gene expression, 
differentiation, apoptosis, malignant transformation and metastasis (76;77), and 
represents one of the most important mechanisms for signal transduction induced by 
extracellular stimuli, such as growth factors, hormones and neurotransmitters (78). Once 
activated, PKC translocates from the cytosol to the cell membrane, where it binds to 
anchoring molecules called receptors for activated C kinases (RACKs) which localize 
PKC close to its protein substrates (79). 
 
The PKC family involves 12 isoforms which differ in expression pattern, function, and 
response to extracellular stimuli (80). Depending on their biochemical properties, co-
factor requirements and sequence homology, the PKCs have been divided into three 
subclasses; the classical PKCs (, I, II, and ) are Ca2+- and diacylglycerol (DAG) 
dependent whereas the novel PKCs (, , , 	, 
, and ) are Ca2+-independent but 
respond to DAG. The atypical PKCs (, ) are insensitive to both Ca2+ and DAG 
(81;82).  
 
Being a target for growth factors as well as a receptor for tumor promoting agents, PKC 
plays a major role in tumorigenesis (83). The PKC-isoenzymes are ubiquitously 
expressed, with the classical PKCs as the most abundantly represented. Among these, 
PKC- is the most thoroughly studied. Abnormal levels of PKC- have been found in 
several transformed cell lines as well as in a variety of human tumor tissues, including 
malignant melanoma (84). Even though there are conflicting results, the vast majority of 
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the studies report an association between PKC- activation and increased motility and 
invasion of cells, and favour the role of PKC- as an inducer of proliferation and a 
suppressor of apoptosis (84). Activation of PKC has been demonstrated to affect both 
the MAPK/ERK1/2 and the PI3-K pathways, as well as GSK-3 and nuclear factor 
kappa B (NFB) (83;85;86). 
 
Chemical tumor promoters have been identified as specific PKC activators. Phorbol 12-
myristate 13-acetate (PMA) is a tumor promoting phorbol ester which binds to the 
DAG-binding site of PKC and causes its activation followed by malignant 
transformation. Tobacco smoke contains PKC activating substances, such as catechols 
and hydroquine, considered to act in a tumor promoting way. Moreover, high 
consumption of dietary lipids may be followed by cancer initiation carried out partly via 
PKC activation (83). 
 
5.5. FABP7 
 
Fatty acid binding protein 7 (FABP7), also known as brain lipid binding protein 
(BLBP), belongs to a family of structurally related proteins showing tissue specific 
patterns of expression. The FABP family is divided into two main groups: those 
associated with the plasma membrane (FABPPM) and those associated with the 
cytoplasm (FABP7C) (87). Nine tissue-specific cytoplasmic FABPs have been identified 
so far; FABP1 - FABP9, mainly expressed in liver, intestine, heart, adipose tissue, 
epidermis, ileum, brain, peripheral nervous system and testis, respectively (88).  FABP7 
is highly expressed in radial and Bergmann glia cells throughout the developing nervous 
system (89;90) and is involved in lipid metabolism, including uptake and intracellular 
trafficking of fatty acids and retinoids. In addition, the FABP7 protein has been shown 
to play a role in gene regulation, cell signalling, cell growth and differentiation (88;91).  
Several members of the FABP family have been reported to be differentially expressed 
in cancer. The FABP1 level has been shown to decrease with progression of colon 
cancer (92) while loss of expression of FABP4 was reported in bladder cancer (93). On 
the other hand, both FABP1 and FABP2 are over-expressed in prostate and breast 
cancers (94-97), and  high FABP7 expression in glioblastomas is related to poor 
prognosis (98). Moreover, the FABP5 expression level was recently demonstrated to be 
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increased in prostate cancer as compared to normal tissue and prostatic hyperplasia, and 
was further associated with poor prognosis (94;99). Two recent studies have addressed 
the expression of FABP7 in melanoma tissue and cell lines. deWit et al. demonstrated 
that FABP7 was down-regulated in primary and metastatic malignant melanomas 
compared to benign nevi (100), while Goto et al. found FABP7 to be frequently 
expressed in malignant melanomas and involved in proliferation and invasion of 
melanoma cells. Hence, it has been suggested that FABP7 plays a role in malignant 
melanoma tumor progression (101).  
 
5.6. Malignant melanoma 
 
Melanoma is a malignant tumor originating from melanocytes, the pigment-forming 
cells of the skin. Melanocytes are derived from the neural crest (ectoderm), and during 
embryogenesis these cells migrate to different body areas, such as the skin, uvea (eye), 
and mucous membranes. Thus, melanoma can develop at all these sites, although 
cutaneous melanoma occurs most frequently (102;103). 
 
5.6.1. Melanoma subtypes 
 
Melanomas are morphologically divided into 4 main subgroups; superficial spreading 
melanoma, nodular melanoma, acral lentiginous melanoma and lentigo maligna 
melanoma (102;104-106). Superficial spreading melanoma accounts for approximately 
70%-80% of all melanomas. Nodular melanoma arises in about 10% of the cases, and is 
recognized by its rapid growth into a uniformly blue-black dome-shaped nodule (105). 
Acral lentiginous melanoma is not attributed to sun exposure, and arises predominantly 
on acral surfaces like palms, soles and under the nails (106). Lentigo maligna melanoma 
occurs primarily on sun-exposed skin of elderly patients, mainly located on the head and 
neck. Superficial spreading melanoma, acral lentiginous melanoma and lentigo maligna 
melanoma initially have a phase of radial growth that may last for weeks, months or 
years before progression to a vertical growth phase which increases the risk of 
metastasis. Nodular melanomas do not have this initial radial growth phase (105). This 
morphological classification has, however, been superseded by a system based on the 
histopathological parameters of excised lesions. The classification of melanoma is now 
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based on the vertical diameter of the lesion from the granular cell layer of the epidermis 
to the deepest detectable melanoma cell (tumor thickness) (107;108). 
 
5.6.2. Epidemiology, etiology and risk factors 
 
There are about 160 000 new cases of malignant melanoma worldwide each year, of 
which almost 80% are in North America, Europe, Australia and New Zealand. The 
disease occurs predominantly in white-skinned people (Caucasians), living in countries 
exposed for high intensity ulatraviolet (UV) radiation (2;108). As much as 80% of 
malignant melanomas are caused by UV-damage to the skin during childhood and 
adolescence. Other risk factors, although rare, include congenital nevi, 
immunosuppression and excessive use of solaria (108). Melanoma patients also include 
those who have a sensitive skin type that freckle easily, a history of sun exposure, 
multiple common or dysplastic moles, a personal or family history of other types of skin 
cancer (squamous or basal cell carcinoma) or malignant melanoma (109). Most of the 
malignant melanomas occur sporadically, while around 5 % are hereditary, so called 
familial malignant melanoma (110). The incidence of cutaneous malignant melanoma 
has been rising in most European populations over the past 50 years (2), but accounts for 
only 4 % of dermatological cancers. However, it is responsible for 80 % of deaths from 
skin cancer. Only 14 percent of patients with metastatic malignant melanoma survive for 
five years (111). 
 
 
 
 
Figure 6. The age-specific incidence rate of melanoma in Norway 1997-2001. Reprinted by permission 
from the Norwegian Cancer Registry, ref. (112).   
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5.6.3. Melanoma stages and prognostic factors 
 
The most recent changes to the American Joint Commission on Cancer (AJCC) 
malignant melanoma staging system was in 2002 (113). Stage I and II tumors are 
classified based on thickness, according to Breslow (114), with tumors less than 1 mm 
and between 1 and 4 mm respectively, and no spreading beyond the primary site. At 
stage III, the tumor involves regional lymph nodes and at stage IV, the tumor involves 
metastasis at a distant site (115). Tumor thickness together with ulceration, lymph node 
involvement and distant metastasis are regarded as the the most reliable prognostic 
predictors currently available in cutaneous melanoma (116;117).  In addition, patient 
age, gender, tumor location, level of invasion, tumor vascularity, lymphovascular 
invasion and microsatellites have all been shown to correlate with poor prognosis 
(118;119). The clinical features of melanoma are asymmetry (A), a coastline border (B), 
multiple colours (C), a diameter greater than 6 mm (D), and as the malignant melanoma 
progresses, elevation (E) (108). This ABCDE detection system has been the basis for 
clinical diagnosis for many years. Early melanoma (stage I) is often curable with 
surgery, with a 5 year survival rate above 88% in men and 90% in women. When spread 
to regional lymph nodes (Stage III), the 5 year survival is between 50% and 60% for 
men and women, respectively. Most patients with distant metastases (stage IV) are 
incurable, and the 5 year survival decreases to 8% in men and 20 % in women (112). 
 
5.6.4. Melanoma progression  
 
Human skin consists of three separate layers: Epidermis, dermis and subcutis. The 
melanocytes are localized in the lower part of epidermis, in the basal layer which 
separates epidermis from dermis. This is the site at which most malignant melanomas 
occur. 70 % of malignant melanomas incidents originate from unblemished skin, while 
around 30% have their origin in benign nevi (2). 
 
Melanomas are histologically classified according to their location and stage of 
progression. According to the Clark model of melanoma progression (104) there is a 
stepwise transformation from normal melanocytes to malignant melanoma (Figure 7). 
Stage I involves commom aquired or congenital benign nevi, stage II involves dysplastic 
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nevi, with structural and architectural atypia, stage III is termed the radial growth phase 
(RGP) melanoma, often described as in situ melanoma, which grows laterally and 
remains largely confined to the epidermis. Transition from this stage to the vertical 
growth phase (VGP) in which the cells both invade the upper layer of epidermis and 
penetrate into the underlying dermis and subcutaneous tissue through the basement 
membrane, is the crucial step of the development of melanoma (stage IV). This stage is 
associated with acquisition of metastatic potential and poor clinical outcome (Stage V) 
(120).  
 
 
 
Figure 7. Simplified structure of the skin, and the classical melanoma progression model. Reprinted by 
permission from Massachusetts Medical Society : ref. (111), © 2006. 
 
 
5.6.5. Molecular changes in melanoma 
 
5.6.5.1. Familial melanoma 
 
The transition from benign nevi to dysplastic nevi involves molecular alterations that 
affect cell growth, DNA repair and the susceptibility to cell death.  
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In 25-40% of familial melanoma cases there is a mutation in CDKN2A, the gene 
encoding for the tumor suppressor genes, p16INK4A (INK4) and p19INK4d (ARF) (111). 
Also, 2 % of the families have hereditary mutations in the CDK4 gene affecting the 
INK4 binding site (121;122). 
The risk of developing a melanoma in CDKN2A mutation carriers is high, but it varies 
with geographical localization as in sporadic melanoma, with increased incidence in 
Australia (91%) as compared to European countries (58%) (123). 
 
5.6.5.2. Sporadic melanoma  
 
In non-familial melanoma, 20-50% of the patients show an inactivating mutation in the 
tumor suppressor gene, PTEN (Phosphatase and tensin homologue deleted on 
chromosome ten), leading to over-activation of the PI3K pathway, known to play a 
major role in melanoma progression (111). Activation of the MAPK pathway is also 
very common in melanoma (124). In about 15 % of the cases, the activation is caused by 
mutations in N-RAS (125;126). However, it has been reported that 60-70 % of 
melanoma patients carry mutations in B-RAF (V600E) (127). As mutations in N-RAS 
and B-RAF occur independently of each other, almost all melanomas have some degree 
of MAPK activity (128). So far, B-RAF is the only gene known to be altered in the 
majority of sporadic melanomas (110), however, B-RAF is also shown to be mutated in 
most benign nevi (127-131) and it is suggested that mutated B-RAF may induce 
senescence in these pre-malignant lesions (132). 
 
KIT is a RTK which promotes survival through both the MAPK and PI3K pathways, 
and amplification and activating mutations of the KIT gene are observed in 14% of 
melanomas (133). 
 
The microphtalmia-associated transcriptional factor (MITF) is essential in melanocytic 
differentiation, and amplifications of the MITF gene have recently been demonstrated in 
10% of primary melanomas and 20% of metastatic melanomas. However, its oncogenic 
function seems to appear mainly in cooperation with mutated B-RAF. Nevertheless, 
reduction of MITF activity has been shown to increase the sensitivity to 
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chemotherapeutic agents. Thus, MITF is a potential future therapeutic target in 
melanoma patients (134).  
 
 Cadherins are multifunctional transmembrane proteins that sustain cell-cell contacts, 
form connections with the actin cytoskeleton and influence intracellular signaling. They 
are divided into three subtypes: E (epithelial), P (placental) and N (Neural) (111). 
Progression from RGF to VGF is recognized by loss of E-cadherin and increased N-
cadherin expression. By interacting with other N-cadherin expressing cells, such as 
dermal fibroblasts and the vascular endothelium, melanomas are able to metastasize. 
 
The intracellular domain of E-cadherin is associated with a large protein complex that 
includes -catenin, a protein playing an important role in cell adhesion as well as cell 
signaling. The Wnt/ -catenin signaling pathway has been shown to be involved in the 
formation of many cancers, including melanoma, and several of the components in this 
pathway, such as APC, ICAT, LEF1 and -catenin itself, are modified during melanoma 
progression. In addition to its role in cell adhesion, -catenin signaling is also important 
in promoting cell proliferation, leading to transcription of proliferation inducing genes 
like c-Myc, MITF, cyclin D1 and MMP-7 (42;135).  
 
Transition from RGF to VGF is associated with increased expression of the integrin 
V3, a protein that is responsible for degradation of collagen in the basement 
membrane via induction of matrix metalloproteinase 2 (MMP-2). V3 ligation also 
increases the expression of the pro-survival Bcl-2 gene, and stimulates the motility of 
melanoma cells through re-organization of the cytoskeleton (111). 
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6. EXPERIMENTAL CONSIDERATIONS 
 
6.1. Material 
 
The patient material used in paper I, II and IV was selected from a malignant melanoma 
archive derived from patients undergoing surgery at the Norwegian Radium hospital and 
regional hospitals since the 1980s. Research on this material has been approved by The 
Regional Committee for Medical Research Ethics in Norway.  
 
6.2. In vitro cell cultures 
 
In order to study biological effects, cells derived from organ tissues are grown as in vitro 
cell cultures. Culture conditions vary widely for each cell type, and variation of 
conditions for a particular cell type can result in different phenotypes being expressed.  
 
The most commonly varied factor in culture systems is the growth medium, which 
supplies nutrients and growth factors. Animal serum added to the media is widely used 
to supply the cells with hormones that stimulate cell growth and attachment, as well as 
hormone carrying proteins, lipids and minerals (136). However, when changing batches, 
and sometimes the supplier of serum as well as media, problems might occasionally 
occur. We have not identified any differences in our cell cultures due to such changes, 
but exact growth conditions cannot be guaranteed. Moreover, it is estimated that about 
20% of human cell lines are not the kind of cells they were generally assumed to be. The 
reason for this is that some cell lines, which grow faster and more vigorously than 
others, can cross-contaminate cultures of other cell lines and in time overgrow and 
displace the original cells (137). 
  
6.3. Measurement of cell viability and apoptosis 
 
In paper III we measured cell viability and apoptosis using simple ELISA detection 
systems. Viability was measured using the MTS-assay (Cell Titer Aqueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, WI) which is a colorimetric 
method for detecting the amount of living cells. The colored end product is linearly 
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correlated to the dehydrogenase activity in metabolically active cells. However, viable 
cells are not necessarily the same as proliferating cells, and other methods should be 
added for evaluating proliferation. Apoptosis was measured using The Cell Death 
ELISA Plus Kit (Roche Diagnostics, Mannheim, Germany). This assay determines the 
enrichment of histone-complexed DNA fragments (mono -and oligonucleosomes) in the 
cytoplasm of apoptotic cells. Although the ELISA results in paper III did correlate with 
the proliferation assay, the methods have proven to be less accurate, and other methods 
are needed to validate these results. Thus, in paper IV we used [3H]-thymidine 
incorporation to measure proliferation rates as well as measuring apoptosis-induced 
DNA fragmentation by the TUNEL (terminal deoxynucleotidyl transferase end labeling) 
assay. Moreover, viability of cells was always evaluated visually, in light microscope. 
Occasionally, the cells were stained with Tryphan blue, which is incorporated in dead 
cells, and blue cells were counted to get a more exact overview of the amount of dead 
cells. The results were further confirmed by detecting protein expression of proliferation 
and apoptotic markers by Western blotting.  
 
6.4. Transfection experiments 
 
RNA interference (RNAi) represents a form of post-transcriptional gene silencing 
(PTGS). Artificially synthesized single interference RNA (siRNA) is incorporated into a 
RNA-induced silencing complex (RISC) which probes the target mRNA for 
complementary sequences and then mediates mRNA cleavage followed by gene 
silencing. Antisense oligonucleotides are also used in this manner. Antisense-RNA bind 
to mRNA strands and prevent protein translation while antisense DNA can be used to 
target a specific, complementary RNA sequence. Transfer of siRNA or antisense 
oligonucleotides into cells has now become a routine tool for investigating gene function 
and biological pathways. 
 
In paper III we used antisense oligonucleotides targeting PKC-. The set of 
oligonucleotides as well as procedure were chosen based on the findings of Dennis et 
al., who first reported decreased malignancy in nude mice following PKC- 
downregulation in human melanoma cells (138). Simultaneously, the same 
oligonucleotides were used in a clinical trial at the Norwegian Radium Hospital. In 
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paper IV we used transient transfection of FAPB7 specific siRNA (Stealth RNAi, 
Invitrogen, San Diego, CA) in order to study the effect of down-regulation of FABP7 in 
the early stage melanoma cell line WM35 and the metastatis-derived cell line WM239. 
The method was optimized to achieve the greatest amount of target-specific knock-down 
of expression, as well as a low rate of cell death in control cells. We transfected the cells 
with three different sets of oligonucleotides at three different concentrations (200 nM, 
100 nM and 50 nM). The best results were obtained with 50 nM siFABP7 
oligonucleotide set #1 or Stealth RNAi negative control duplex (Medium GC Duplex) in 
combination with 50 nM LipofectamineTMRNAiMAX transfection reagent (all reagents 
from Invitrogen). The negative siRNA control affected cell viability as the amount of 
living cells decreased compared to untreated cells.  Hence, the effect of siFABP7 had to 
be related to the negative siRNA control and not to untreated cells. 
 
6.5. Microarray 
 
In paper IV we used gene expression profiling (Affymetrix) to identify differentially 
expressed genes in WM35 cells grown as multicellular aggregates (spheroids) after 
treatment with the PKC activator, PMA, and/or the MEK1 inhibitor, PD98059. cDNA 
microarray expression analysis was performed using commercial slides (Affymetrix 
U133 Plus 2.0 arrays, Affymetrix, Santa Clara, CA), containing 47 000 probes of high 
specificity. Three hybridizations were performed, from three biological experiments, 
using untreated monolayer WM35 cells as a reference. The analysis was done 
commercially, and resulted in a variety of up and down-regulated genes. To avoid false 
positive results a 2.5 fold change in ratio was defined as a cut off, which is quite strict, 
and it should be taken into consideration that other interesting genes might have been 
excluded. The microarray results needed to be confirmed, and both real- time RT-PCR 
and Western blotting were used to validate selected results. 
 
6.6. Immunohistochemistry 
 
In paper I, II and IV we performed immunohistochemistry on paraffin embedded tissue 
using commercially available polyclonal antibodies against pJNK, p38 and FABP7. 
pERK1/2 was detected with a monoclonal antibody. Cross-reactivity might occur due to 
sequence homology between different proteins. To validate the specificity of our 
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antibodies, western blot was performed to confirm the size of the protein.  The 
immunohistochemical methods were optimized by qualified persons. All series included 
positive control samples. Negative controls included substitution of the primary 
antibody with mouse myeloma protein of the same subclass and concentration as the 
mono/polyclonal antibodies used. All controls gave satisfactory results. In paper I we 
used the biotin-streptavidin-peroxidase (ABC) method for detection of activated 
ERK1/2. This method is still in widespread use, but the presence of endogenous biotin in 
tissues can lead to increased background staining. Formalin fixation and paraffin 
embedding decreases the endogenous biotin level, but the biotin might recover when the 
tissue sections are treated with heat prior to hybridization. To avoid these limitations, 
methods that do not rely on biotin have been developed. The EnVision+ system, used in 
paper II and IV, is based on a polymer backbone which is attached to multiple enzymes 
as well as secondary anti-mouse or anti-rabbit antibodies. Therefore, the method can be 
used to detect any tissue bound protein of mouse or rabbit origin. Besides being both 
easier and more time saving, EnVision + has also been shown to be equally, if not more 
sensitive than biotin based methods. The substrate used also varied between the 
experiments. In paper I and paper IV, diaminobenzidine tetrahydrocloride (DAB) was 
used, and since the resulting staining is brown, it can be difficult to separate stained 
proteins from melanin within the cells. Therefore we also tried 3-amino-9-
ethylcarbazole (AEC), which gives a red staining. However, the scoring was done by an 
experienced pathologist, and should be reliable regardless of the substrate used. Since 
only 1 of 10 000 cells in a primary tumor is able to metastasize, it is important to 
identify tumor subpopulations that have markers of increased aggressiveness. We 
therefore chose the 5 % cut off to distinguish between negative and positive cells. 
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7. BRIEF SUMMARY OF PAPERS 
 
Paper I: Expression of activated extracellular signal-regulated kinases 1/2 in 
malignant melanomas: Relationship with clinical outcome. 
 
The protein expression of activated extracellular signal-regulated kinases 1 and 2 
(ERK1/2) in a panel of benign nevi, primary and metastatic melanomas was examined 
by immunohistochemistry and correlated to clinicopathological parameters and cell 
cycle markers. We found a heterogeneous expression of activated ERK1/2 in primary 
and metastatic lesions, with a decrease in the expression level in the metastases 
compared to the primary melanomas. No immunoreactivity was detected in benign nevi. 
When analyzing the melanoma subgroups separately, we found that activated ERK1/2 
expression varied significantly with the thickness of superficial spreading melanomas, 
with lower expression in thinner lesions (Mann-Whitney P=0.016). We also observed 
significant correlation between activated ERK1/2 and cyclin D1 (P=0.031) in nodular as 
well as between activated ERK1/2 and cyclin D3 (P=0.030) in superficial spreading 
primary melanomas. The protein level of p27Kip1 correlated with nuclear ERK1/2 
activation (P=0.048) in superficial spreading melanomas. Furthermore, a strong 
correlation between activated ERK1/2 and membrane bound β-catenin (P=0.004) in 
nodular melanomas was revealed. Activation of ERK1/2 did not have any impact on 
relapse-free or overall survival.  In conclusion, these results suggest that activation of 
ERK1/2 may be involved in cell cycle regulation in superficial spreading melanomas. In 
the nodular subtype ERK1/2 activation might lead to destabilization of membrane bound 
β-catenin. 
 
Paper II: Activation of c-Jun N-Terminal Kinase (JNK) is associated with cell 
proliferation and shorter relapse-free period in superficial spreading malignant 
melanoma  
 
The panel of benign nevi, primary and metastatic melanomas were 
immunohistochemically analyzed for expression of the activated MAPK family 
members, p38/MAPK (p-p38) and JNK (p-JNK). The findings were correlated with 
known prognostic variables and cell cycle markers. There was a heterogeneous 
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expression of both p-JNK and p-p38, with increased expression in the metastases for 
both proteins. Surprisingly, while only 7 % of the benign nevi showed positive 
immunostaining for p-p38, 73.5% of the benign nevi showed strong activation of JNK. 
When separating the melanoma subgroups, we found that high level of cytoplasmic p-
JNK was associated with thicker tumors (P=0.017) and shorter disease-free survival 
(P=0.003) in patients with superficial spreading melanomas. Moreover, cytoplasmic p-
JNK correlated with cyclin A (P=0.017) and p21 (P=0.021) in the same patient group. In 
patients with nodular melanomas, nuclear p-p38 was associated with Ki-67 expression 
(P=0.012), but neither cytoplasmic nor nuclear localized p-p38 was associated with 
disease outcome. All three MAPK signaling pathways were positively correlated to each 
other in superficial spreading melanoma, and p38 activation was also positively 
associated with   p-Akt (P=0.047) in this melanoma subgroup. In contrast, except for a 
positive correlation between nuclear p-p38 and membranous p-TrkA (P=0.02), no 
correlation between the activation status of the different signaling pathways was 
observed in nodular melanomas. In conclusion, our results suggest that activated JNK in 
benign nevi may have a role in restricting uncontrolled cell proliferation or survival. 
However, during tumor progression the functional role of JNK activation is switched, 
and activated JNK is associated with cell proliferation and shorter relapse-free period. 
Alltogether, these results suggest that the JNK activation status may be a marker for 
clinical outcome for patients with at least the superficial spreading subgroup of 
malignant melanoma. The activation status of p38, on the other hand, seems to play a 
less important role in development and progression of malignant melanomas. 
 
Paper III: Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-
independent growth and survival of melanomas through MEK-independent 
activation of ERK1/2 
 
In this study we examined the effect of the PKC activating tumor promoting phorbol 
ester, PMA, on proliferation and survival of melanoma cells grown as multicellular 
aggregates in suspension (spheroids). In contrast to what was found in monolayer cells, 
PMA increased cell proliferation in spheroids. Interestingly, we also observed that PMA 
protected melanoma cells against suspension induced apoptosis (“anoikis”). To further 
elucidate whether PKC was of importance for the ability of melanoma cells to 
proliferate and survive in suspension, anoikis-resistant melanoma cell lines were 
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transfected with antisense oligonucleotides directed against the PKC- isoenzyme or 
treated with the general PKC inhibitor Gö6976. We found that PKC down-regulation 
was associated with a strong induction in suspension induced cell death. Of particular 
interest, we provided evidence of PMA-mediated activation of ERK1/2 independently of 
its upstream activator, MEK1/2. In conclusion, our results suggest that PMA increases 
anchorage-independent growth at least partly through PKC activation and MEK-
independent activation of ERK1/2. 
 
Paper IV: The fatty acid protein 7 (FABP7) is involved in proliferation and 
invasion of melanoma cells 
 
We used gene expression profiling (AffymetrixTM) in order to identify genes that are 
involved in PMA induced survival of melanoma spheroids (Paper III). Among the most 
significantly differentially expressed genes was the fatty acid-binding protein 7 
(FABP7). We found that FABP7 mRNA and protein levels were down-regulated 
following treatment of melanoma cell lines with PMA and/or the MEK1 inhibitor 
PD98059. Moreover, down-regulation of FABP7 using siRNA decreased cell 
proliferation and invasion, but did not affect apoptosis. The protein expression of 
FABP7 were immunohistochemically analyzed in a panel of benign nevi, primary and 
metastatic melanomas and correlated to clinicopathological parameters and cell cycle 
markers. FABP7 was heterogeneously expressed, with the highest expression levels in 
nevi compared to primary and metastatic lesions. In superficial spreading melanomas we 
observed positive correlation between cytoplasmic FABP7 and tumor thickness (P = 
0.021) as well as a trend for correlation with Ki-67 scores (P = 0.070). A trend for 
negative association between cytoplasmic FABP7 expression and relapse-free survival 
(P = 0.069) was also observed in this patient group. Taken together, these results suggest 
that FABP7 can be regulated by both PKC and the MAPK/ERK1/2 pathway in 
melanoma cells, but is not involved in anoikis. Furthermore, FABP7 is involved in cell 
proliferation and invasion in vitro, and may be associated with melanoma progression. 
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8. RESULTS AND DISCUSSION 
 
8.1. Expression and subcellular localization of MAPK 
 
In paper I and paper II we reported the immunohistochemical staining of activated 
ERK1/2, JNK and p38 in a panel of primary and metastatic human malignant 
melanomas as well as benign nevi. In agreement with other studies (60;139-146), we 
observed a heterogeneous cytoplasmic and/or nuclear staining pattern for p-Erk1/2 
(54%), p-JNK (35%) and p-p38 (25%) in the primary malignant melanomas. Activated 
ERK1/2, p38 and JNK was found in cytoplasm alone in 21 %, 13 % and 6 % of the 
tumors, respectively, whereas exclusively nuclear staining was found in 3 % for p-
ERK1/2, 7 % for p-p38 and 21 for p-JNK.  
 
Interestingly, a lower number of tumors expressed activated ERK1/2, p38 and JNK in 
the metastases compared to the primaries, as only 33 %, 9 % and 25 % showed positive 
immunostaining in the cytoplasm and/or nucleus, respectively. The reason for this 
decrease needs to be elucidated, but there has been increasing evidence that the MAPK 
phosphatases (MKPs/DUSP-proteins), which negatively regulate MAPKs, can be 
abnormally regulated in certain types of cancer (147). Thus, it may be speculated that 
over-expression of MKPs can contribute to dephosphorylation and inactivation of 
MAPKs in the metastases. 
 
While several studies have revealed that B-RAF mutations are very frequent in both 
malignant melanoma and benign nevi (127-131), our results showed no 
immunoreactivity of p-ERK1/2 in benign nevi (paper I). This observation is supported 
by other studies (148-150), strongly suggesting that B-RAF mutation is not sufficient to 
activate the RAS-RAF-MEK-MAPK pathway in melanoma tissue. The lack of 
correlation between B-RAF mutations and activation of ERK1/2 could be explained by 
additional inhibitory mechanisms that suppress the expression or activity of B-RAF or 
its downstream targets (148). Melanocytes, like other normal cells, have defense 
mechanisms against oncogenic activation, and involved in this defense are the MKPs, 
resulting in dephosphorylation and inactivation of MAPK kinases (147). It has 
previously been shown that MKPs are not present in atypical nevi, further suggesting 
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that loss of MKP activity may be a part of early melanomagenesis (151). To the best of 
our knowledge, there have been no studies on MKP expression in benign nevi, but it is 
reasonable to suggest that MKPs have a protective role by inactivating MAP kinases in 
these lesions.  
 
Another inhibitory molecule that could explain the lack of ERK1/2 activity in benign 
nevi is the RAF kinase inhibitor protein (RKIP), which prevents MEK activation by 
RAF-1. Recently, it was shown that the expression of RKIP decreased in primary 
melanoma tissue as compared to benign nevi (152). Finally, most benign nevi do not 
progress to melanoma but are growth arrested, establishing a senescent state which 
needs to be evaded before further melanoma progression (153).  It has been questioned 
whether this senescence is induced by B-RAF. For example, it has been shown that 
sustained B-RAF expression in human melanocytes induces cell cycle arrest which is 
accompanied with hallmarks of senescence, like up-regulation of p16INK4 and 
senescence associated acidic -galactosidase (SA--GAL) (154). In a recent study it was 
revealed that oncogenic B-RAF induced senescence and apoptosis through an 
autocrine/paracrine pathway which involved insulin growth factor binding protein 7 
(IGFBP7) (155). 
 
It has also been suggested that Akt3 in the PI3K pathway cooperates with mutated B-
RAF in promoting melanoma development by directly phosphorylating and thereby 
inactivating the B-RAF protein, decreasing ERK1/2 activity to a level that enhances 
rather than inhibits melanocytic cell proliferation (156).  
 
Only 7 % of the nevi showed positive immunostaining for p-p38 (paper II). Similary to 
ERK1/2 activation, the biological effect of p38 depends on the strength and duration of 
its activity. Following stimulus, p38 is transiently activated within a very short time 
(157). Supporting our suggestion that the MKPs are active in benign nevi, it is 
reasonable to hypothesize that p38 is instantly dephosphorylated in early stage 
melanoma. In contrast, a total of 74 % of the nevi were positive for p-JNK, a finding 
which is contradicted by Kunz et al. (158) who showed no p-JNK immunoreactivity in 
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benign nevi.  This discrepancy, however, could be explained by the small number of 
nevi tested by Kunz et al. compared to our study (8 vs.27). Moreover, it is possible that 
they have used a higher cutoff, which will define a larger number as negative. Further 
supporting our findings is the fact that benign nevi are located on the skin surface where 
they are thoroughly exposed to UV-radiation.  UV exposure may result in JNK 
activation followed by induction of c-jun, activation of the AP-1 transcription factor 
complex and apoptosis (159;160).  As discussed by Shen et al. (161), sustained 
activation of JNK has been shown to suppress ERK1/2 activation in transformed liver 
cell lines, a finding which may partly explain the high expression of p-JNK and the low 
expression of p-ERK1/2 in benign nevi.  Interestingly, JNK activation in the benign nevi 
was solely localized to the nucleus, which suggests that JNK is involved in 
transcriptional regulation. Our results, alltogether, suggest that neither ERK1/2 
activation nor p38 activation play key-roles in the early stages of melanoma 
development, and that the profound JNK activation has a protective role restricting 
uncontrolled growth or survival of the nevus cells.  
 
8.2. MAPK in a clinical setting   
 
In paper I and II we examined whether activation of the different MAPK pathways has 
any impact on clinical outcome for melanoma patients. As described in the chapter 
above, there was a decline in ERK1/2 activation as well as in JNK and p38 activation in 
the metastases compared to the primary melanomas. These results are, however, 
supported by studies showing an inverse correlation between ERK1/2 activation and 
progression of prostate cancer (162;163). Similarly, deactivation of JNK and p38 
concomitant with increased tumor aggressiveness has been previously described in rat 
prostate and human colon cancer (164;165) and JNK activation has been associated with 
early-stage non-small cell lung cancer (145). Deactivation of p38 has also been 
associated with progression of hepatocellular carcinomas (164). Hence, it has been 
speculated that deactivation of p38 and JNK in advanced tumors provides cells with an 
anti-apoptotic mechanism and growth advantage (52). 
 
The ERK1/2 pathway and the PI3K pathway are both activated in different types of 
cancer (53;166), and cross-talk between these two pathways has been reported (167-
169). It has been shown that inactivation of ERK1/2 by the PI3K pathway accompanies 
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disease progression, and that phospho-Akt is able to inactivate RAF and thereby its 
downstream targets (17;162;163;170). This is, however, contradicted by our group’s 
recent findings, showing activated Akt in both benign nevi and in primary and metastatic 
melanoma tissue, as well as a positive association between p-Akt  and p-ERK1/2 in 
superficial spreading melanomas (171). The positive correlation between these two 
pathways may be explained by their simultaneous parallel activation instead of the 
influence on each other (171).  
 
Although our panel of melanomas has not been examined for over-expression or 
mutations in the RAS genes, it is of interest to note that N-RAS mutations have been 
associated with better clinical outcome for melanoma patients (172-174) which may 
partly explain the observed decline in the activation of ERK1/2, JNK and p38 in 
metastases.  
 
Our results showed that activated ERK1/2 expression varied significantly with tumor 
thickness for patients with superficial spreading melanoma, with less expression in 
thinner tumors. No association to relapse-free or overall-survival was, however, revealed 
(Paper I). These results are supported by a study by Branca et al. who reported no 
association between phosphorylated ERK1/2 and clinical outcome in cervical cancer 
(175), but are in contrast to studies on pancreatic carcinoma and liver cancer, in which 
poor prognosis was associated with ERK1/2 activation (60;141;143;176;177). 
Similarily, in a study by Svensson et al. (178), ERK1/2 activation correlated with 
smaller tumors and a less aggressive tumor type, as well as with better prognosis in 
untreated breast cancer patients. In vitro studies, however, suggest that sustained 
activation of ERK1/2 may lead to transformation in some but not all cell types (59). 
Together, these results suggest that the importance of the ERK1/2 signaling pathway in 
tumor progression may be tumor specific. 
 
 In paper II we showed that high levels of cytoplasmic p-JNK was associated with 
thicker tumors and shorter relapse-free survival in patients with superficial spreading 
melanoma, while there was no correlation between p38 activation and clinical 
parameters. Earlier studies have demonstrated that activation of JNK and p38 is 
associated with poor prognosis for patients with breast cancer (140;179), while one 
study also showed correlation between JNK phosphorylation and prolonged recurrence-
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free survival (180). Moreover, in a study by Aguirre-Ghiso et al. (181), they report that 
in breast, prostate, melanoma and fibrosarcoma cell lines, the ratio between ERK1/2 and 
p38 signaling was significant for cell behaviour and prognosis. A high ERK1/2/p38 ratio 
enhanced cell proliferation and growth while an inversion of this ratio caused cell cycle 
arrest and dormancy in vivo. In contrast to the other cell lines tested in the study by 
Aguirre-Ghiso et al., the melanoma cell line used (M24met) seemed to escape this 
negative feedback mechanism by p38, and remained tumorigenic. However, we cannot 
conclude that the ratio between ERK1/2 and p38 signaling is of no importance in our 
melanoma panel, based on previous results from one, single cell line.  
 
About half of the p38 substrates identified so far are transcription factors, pointing at 
p38 in having a role in gene regulation at a transcriptional level (182). However, with 
only a small proportion of melanoma specimens showing positive p38 immunostaining, 
and with an even smaller percentage showing nuclear expression we suggest that gene 
regulation is not a major task for p38 in malignant melanoma. Moreover, Aguirre-Ghiso 
et al. suggested that the p38 pathway may be altered or dysfunctional in melanomas 
(181). Also, p38 is stimulated by a multiplicity of external factors, mediating a variety of 
p38 signaling pathways, which is dependent on cell type (182).  
 
Like p38, JNK has many nuclear substrates with both tumor suppressive as well as 
oncogenic effects. It has been emerging evidence that phosphorylation of non-enzymatic 
scaffold or adaptor proteins by JNK and other MAP kinases may alter the interactions 
with their binding partners and thereby mediate changes in the signaling pathways (56). 
With this in mind, it is possible for cytoplasmic JNK to alter its signal transduction 
pathway and thereby induce cell transformation.  
 
Taken together, our results suggest different roles of the MAPKs in disease progression, 
and that more than one signaling pathway is involved in development and progression of 
a malignant phenotype.  
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8.3. Relationship between the expression of MAPK and cell cycle markers 
 
Inappropriate regulation of the cell cycle has been demonstrated to play a major role in 
the tumorigenesis of human cancers. In paper I and II we explored the relationship 
between MAPKs and cell cycle markers in melanoma tissue. Several studies, including 
work from our own group, have shown that cyclin D1 is up-regulated in primary and 
metastatic melanoma as compared to benign nevi, suggesting that cyclin D1 is 
associated with proliferation during melanomagenesis (183-186). Knowing that 
activated ERK1/2 could be seen as a proliferative marker in melanoma, we expected an 
association between cyclin D1 and p-ERK1/2. We observed significant correlation 
between activated ERK1/2 and cyclin D1 in nodular melanomas, but surprisingly, only 
cyclin D3 and not cyclin D1 was associated with activated ERK1/2 in superficial 
spreading melanomas.  So far, little is known about the interplay between cyclin D3 and 
cell signaling in human cancer. We have previously reported an association between the 
protein level of cyclin D3, cell proliferation and disease progression in superficial 
spreading melanoma, and suggested that cyclin D3 is the most frequently expressed D-
type cyclin (183).  Supporting these findings, other studies have suggested the D-type 
cyclins to be differentially expressed in cancer, thereby playing different roles 
(187;188). Thus, it may be speculated that in superficial spreading melanomas, ERK1/2 
activation may induce cyclin D3 expression, thereby leading to increased cell 
proliferation and tumor thickness.  The lack of association between cyclin D1 and 
ERK1/2 activation in this melanoma subgroup is also supported by others, showing that 
in a melanoma cell line incubated with a MAPK inhibitor, expression of cyclin D1 
remained unchanged (124). Several studies have provided evidence that the induction of 
cyclin D1 and thereby progression through G1 requires only moderate ERK activity, but 
the activity has to be sustained for several hours (189). It may therefore be speculated, 
that the duration of MAPK activation is not optimal to induce cyclin D1.  
 
Also in support of ERK1/2 regulating cell proliferation in melanoma, we observed a 
trend for correlation between activated ERK1/2 and cyclin A as well as between 
activated ERK1/2 and Ki-67 in superficial spreading melanomas. We have previously 
suggested that both cyclin A and Ki-67 may be prognostic markers for patients with 
superficial spreading melanoma (190). In paper II, we found significant positive 
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association between cytoplasmic p-JNK and cyclin A and p21WAF1/CIP1 in superficial 
spreading melanomas as well as between activated p38 in the nucleus and Ki-67 in 
nodular melanomas. In agreement with our results, Margheri et al. (191) observed a 
decline in JNK phosphorylation concomitantly with inhibition of cyclin D3 and cyclin A 
in response to blocking the urokinase receptor. Moreover, Nuntharatanapong et al. (192) 
and Kim et al.  (193) reported positive correlation between the cdk-inhibitor p21CIP1/WAF1 
and cytoplasmic p-JNK. In contrast to p-JNK, p38 activation was not associated with 
markers of cell cycle progression or disease outcome in superficial spreading 
melanomas (Paper II). In nodular melanomas, on the other hand, the presence of 
activated p38 in the nucleus was associated with Ki-67 expression. However, we have 
previously shown that the level of Ki-67 has little impact on disease progression of this 
subtype (190). Together these findings suggest that p38 does not play a major role in 
development or progression of melanocytic tumors and that the observed activation is 
rather an effect of other signaling pathways. As we also report a positive association 
between activation of ERK1/2, JNK and p38, it is reasonable to suggest a positive cross-
talk mechanism between the three different MAPKs. In addition, we have to take into 
consideration that over-expression of MKK kinases is followed by activation of p38 as 
well as JNK, which might explain why these two pathways are often co-expressed (182). 
 
8.4. ERK1/2 is associated with -catenin 
 
-catenin signaling has been shown to be involved in several types of cancer, including 
melanoma, and in addition to its role in cell adhesion, -catenin also promotes cell 
proliferation through activation of transcription factors (135). We have previously 
shown inverse association between cytoplasmic -catenin and cyclin D1 in superficial 
spreading melanoma and hypothesized that -catenin had a protective role in early 
melanoma development (194). This spurred us to further investigate whether activation 
of the MAPK pathways had any impact on the expression of -catenin. 
 
In paper I we observed inverse correlation between ERK1/2 activation and membrane-
bound -catenin (P=0.004) in nodular melanomas. We suggested that destabilization of 
-catenin following direct or indirect phosphorylation by active ERK1/2 was leading to 
decreased homeotypic interactions and increased invasive potential in this melanoma 
subtype. Interestingly, in a recent study using a mouse melanoma model, Delmas et al. 
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(195) reported that -catenin induced immortalization of melanocytes by suppressing 
p16INK4 expression and that -catenin promoted melanoma progression in cooperation 
with N-RAS. It must be considered that when our melanoma panel was examined for -
catenin expression, only 8 % of the primary lesions were positive, and since the level of 
nuclear staining always was in agreement with the cytoplasmic staining, only 
cytoplasmic and membrane-bound expression was included in the statistical analysis 
(194). A hallmark for the activation of wnt/-catenin signaling in melanoma is the 
presence of -catenin in the nucleus, and about 30 % of melanomas express nuclear -
catenin, suggesting an important role for this signaling pathway in melanoma (135). It 
would therefore be interesting to examine whether ERK1/2 activation is associated with 
the wnt/-catenin signaling pathway. However, we will need to expand our melanoma 
panel to elucidate this.  
 
We did not find any association between activated JNK or activated p38 and the 
expression of -catenin, but a potential correlation cannot be excluded since nuclear 
expression of -catenin was not a part of this study.  
 
8.5 PKC and its influence on MAPK signaling 
 
Several studies have documented the importance of PKC activation in regulating cell 
growth, differentiation and survival (196). It has been anticipated that increased 
activation of PKC- is associated with melanoma progression (84;197-199).  In paper III 
we explored the effect of phorbol-12-myristate-13-acetate (PMA), a potent activator of 
classical and novel PKC isoforms, on growth and survival of human melanoma cells 
grown as multi-cellular aggregates (spheroids). We found that PMA, in contrast to 
monolayer cultures, increased cell proliferation and protected cells from suspension-
induced apoptosis (anoikis). To investigate the impact of PKC in this process, we 
knocked out PKC- using antisense oligonucleotides. Anoikis was strongly induced, a 
finding also supported by Dennis et al. (138), who reported that transfection of human 
melanoma cell lines with antisense oligonucleotides against PKC- suppressed 
metastasis formation in nude mice. We observed, furthermore, that PMA induced 
anchorage-independent growth and reversed the down-regulation of ERK1/2 caused by 
MEK inhibition, suggesting a MEK-independent activation of ERK1/2. To further 
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ensure that the reversible effect of PMA on ERK1/2 activation was mediated by PKC, 
melanoma cells were grown in the presence of both PD98059 and a potent inhibitor of 
all classical PKCs, Gö6976. ERK1/2 can be activated by a variety of signaling events. 
Thus, Gö6976 alone had no effect on ERK1/2 phosphorylation. However, in 
combination with PD98059, Gö6976 at least partly prevented PMA-mediated 
reactivation of ERK1/2. The mechanism for this alternative ERK1/2 activation remains 
to be elucidated. However, a possible explanation might be drawn by linking our results 
from paper II and III together. In paper II, we demonstrated that the JNK and ERK1/2 
pathways are positively correlated to each other. According to Buchner et al., (200), the 
phorbol ester TPA (with similar functionality as PMA) induces JNK activation via the 
classical PKC isoforms, and we may speculate that the MEK-independent activation of 
ERK1/2 upon PMA treatment progresses via the JNK pathway. Moreover, the protein 
tyrosine kinase Src plays a role in cell proliferation, differentiation, adhesion and 
migration, and change in Src activity is involved in growth, progression and metastasis 
in several human cancers, including melanoma (201;202). Recent research has shown 
that increased Src activity protects lung adenocarcinoma and colon cancer cells from 
anoikis (203;204). PKC is a known activator of Src, and we wanted to investigate 
whether Src is our missing link in MEK-independent ERK1/2 activation and anoikis 
resistance in melanomas. However, preliminary experiments do not support this 
hypothesis at present. 
 
It can also be questioned whether the inhibitors used to downregulate ERK1/2 activation 
show the appropriate selectivity. PD98059 inhibits MEK1 only, and even though 
ERK1/2 is significantly downregulated using this inhibitor, it is still a possibility that the 
reversible effect of PMA progresses through MEK2. However, using U0126, a more 
selective inhibitor of both MEK1 and MEK2, we obtained the same results.  
 
Following PMA treatment we also observed increased phosphorylation and deregulation 
of the pro-apoptotic proteins Bad and Bim, which was related to increased activation of 
ERK1/2 and anoikis resistance (Paper III). In support of this, a recent study reported that 
B-RAF mutations induced phosphorylation of Bad and Bim, leading to increased 
anchorage-independent growth of melanoma cells. Moreover,  depletion of both Bad and 
Bim further increased the protection of B-RAF knock-down cells from anoikis, 
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suggesting that the Bad and Bim proteins play a major role in B-RAF regulated 
apoptosis in melanoma cells (38).  
 
Upon activation, PKC will fulfill its effect within a very short time before the protein is 
degraded in the cytoplasm (205-208). In this regard, our group observed increased 
activation of ERK1/2 even after 5 minutes of PMA treatment (data not shown). It is 
uncertain whether the effect of PMA is due to activation or down-regulation of PKC. 
For instance, Lu et al. (209) showed that 3Y1 rat fibroblasts are anoikis resistant when 
treated with TPA.  When Bryostatin 1, previously shown to prevent tumor promotion by 
TPA, was added to TPA treated and untreated cells, they observed increased anoikis and 
that down-regulation of PKC-, but not the other isoforms expressed in this cell type, 
was prevented. Hence, they concluded that down-regulation of PKC- was responsible 
for the tumor-promoting effect of TPA in rat fibroblasts. Our results in paper III, 
however, strongly suggest that PKC activation is responsible for the observed effects of 
PMA. 
 
8.6. FABP7 in melanoma 
 
In paper III we reported that the PKC activator PMA increased cell proliferation and 
promoted anchorage-independent survival of melanoma cells. Furthermore, this 
protective action seemed to be at least partly mediated through PKC and MEK-
independent activation of MEK. In an attempt to identify other genes involved in 
survival and apoptosis of melanoma cells, high throughput gene expression profiling 
was used to identify differentially expressed genes in untreated cells cultured as 
monolayer and spheroids, as well as in spheroids treated with PMA and/or the MEK 
inhibitor PD98059 (paper IV). Among the genes showing highest differentiation was 
fatty acid binding protein 7 (FABP7), a gene that is normally expressed in radial glial 
cells in the brain. However, two recent studies have reported FABP7 expression in 
melanoma (100;101) urging us to pursue this finding. Melanocytes originate from 
progenitor neural crest cells, which also have the potential to differentiate into glial 
cells, and melanoma and glioma cells have many tumor-associated markers in common 
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as well as similar biological properties (210). Hence, the observed expression of a brain 
specific protein in melanoma could be explained by the common origin of melanocytes 
and glial cells. We observed that FABP7 was down-regulated following both PKC 
activation and inhibition of MEK1, but knowing that the two treatments have an 
opposite effect on anchorage-independent survival (paper III), this observation argues 
against FABP7 involvement in promotion of anchorage-independent survival in 
melanoma cells. We further observed that PMA treatment down-regulated FABP7 even 
in the presence of activated ERK1/2, and suggest that this down-regulation is likely to 
be PMA/PKC-mediated but MAPK-independent. We therefore hypothesize that FABP7 
can be regulated independently by both signaling pathways in melanoma cells. 
   
As discussed in paper IV, it has been shown that activation of the MAPK pathway can 
induce increased activity of peroxisome proliferator-activated receptors / (PPAR /). 
Similarly, PKC can both positively and negatively regulate PPAR-dependent 
transcription (211-213). Binding of PPAR to its response element, PPRE, has been 
shown to up-regulate FABP1 and FABP4 (88;214;215). It is reasonable, therefore, to 
assume that FABP7 might also be regulated through this mechanism. 
 
To further clarify the role of FABP7 in melanomas we used siRNA to down-regulate its 
expression in the primary WM35 and metastatic WM239 melanoma cell lines (paper 
IV). This down-regulation significantly inhibited proliferation in both cell lines without 
affecting the degree of apoptosis. Moreover, we showed that down-regulation of FABP7 
negatively influenced the invasive potential of melanoma cells. Our results are supported 
by Goto et al. who demonstrated increased proliferation and unaffected apoptosis, as 
well as reduced invasiveness, in 2 of 6 melanoma cell lines following FABP7 down-
regulation (101). Together these results suggest a role for FABP7 in regulation of 
proliferation and invasion in melanoma.  
 
Several members of the FABP family have been reported to be differentially expressed 
in cancer. Loss of expression of FABP4 has been reported in bladder cancer and FABP1 
and FABP2 have been shown to be over-expressed in prostate and breast cancers (94-
97). We also found, in accordance with others (101), that FABP7 was expressed in both 
primary and metastatic melanoma cell lines. Moreover, in clinical samples, FABP7 
protein expression was increased in nevi compared to primary and metastatic melanoma, 
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while there was no difference in FABP7 expression between the latter two. This is 
further supported by another microarray study where they reported that FABP7 is down-
regulated in malignant melanoma compared to nevi (100). The higher expression of 
FABP7 in nevi compared to malignant melanomas seems contradictory to the in vitro 
data in the present study, as well as to the association with clinical parameters of disease 
progression. We are unable to explain this discrepancy at present. However, the majority 
of benign nevi are terminal lesions that do not progress to melanoma and it is possible 
that the molecular events regulating these processes differ. 
 
Analysis of the clinical data showed that thicker superficial spreading melanomas 
expressed higher levels of FABP7 (paper IV). We also observed a trend towards 
association between high levels of FABP7 and reduced disease-free survival, as well as 
a positive trend between FABP7 and the proliferation marker Ki-67 in these patients. 
This suggests that FABP7 may contribute to disease progression, possibly by increasing 
the cell proliferation and invasive potential of melanoma cells.  
 
In our melanoma cohort we observed heterogeneous expression of the FABP7 protein. 
Such variation in sub-cellular localization of FABP7 has also been reported in 
developing radial glia cells, glioma cell lines (89;216) and glioblastoma multiforme 
(GBM) specimens (217). Since FABP proteins are considered to be co-activators in 
PPAR-mediated gene transcription control, this could in part explain FABP7 
translocation to the nucleus (88). However, nuclear FABP7 expression did not correlate 
with the examined markers or with clinical parameters, which indicates that FABP7 in 
this compartment is of little importance in melanoma progression. 
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9. CONCLUSIONS  
 
In this thesis we have tried to reveal some of the signaling mechanisms underlying 
melanoma development and progression. We show that the MAPK signaling pathways, 
represented by ERK1/2 and JNK, are both involved in this process. We suggest that 
activation of ERK1/2 is associated with cell cycle regulation in superficial spreading 
melanomas and also with -catenin destabilization and decrease in homotypic 
interactions in nodular melanomas (Paper I). Moreover, while activated JNK plays a role 
in restricting uncontrolled cell proliferation in benign nevi, its functional role is switched 
during tumorigenesis, and JNK activation is associated with cell proliferation and 
shorter relapse-free survival in patients with superficial spreading melanoma (Paper II). 
Activation of p38 does not seem to play an important role in melanoma progression. 
 
PMA induces anchorage-independent survival through MEK1-independent ERK1/2 
activation (Paper III). In our search after genes involved in anoikis resistance, 
microarray studies revealed that FABP7 is differentially expressed in melanoma cells 
treated with PKC activating and/or MEK1/2 inhibiting agents (Paper IV). We conclude 
that FABP7 seems to be regulated both by PKC and ERK1/2 through independent 
mechanisms. Moreover, FABP7 is not involved in anoikis resistance, but still we show 
that FABP7 is involved in regulation of cell proliferation and invasion. Finally, FABP7 
is associated with poor prognosis in patients with superficial spreading melanoma. 
 
Alltogether, our results point to the ERK1/2 and JNK signaling pathways, as well as 
PKC and FABP7, as potential targets for melanoma therapy.  
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10. FUTURE ASPECTS 
 
From our studies we know that PMA mediates MEK1-independent ERK1/2 activation 
and survival. To ensure that the observed effect of PMA is actually independent of MEK 
and is not due to some unspecific effects of the inhibitors, we will use siRNA 
oligonucleotides directly targeted against MEK1/2 and then perform the same 
experiments as with the cells treated with pharmaceutical MEK inhibitors.   
 
The pathway from PKC to MEK-independent activation of ERK1/2 remains to be 
elucidated. However, our microarray study has provided us with a great amount of data 
which needs to be further studied. Among several interesting genes that were 
differentially expressed was MKP3, also called DUSP6, which showed a 4 fold down-
regulation in spheroids after treatment with the MEK1 inhibitor PD98059. PMA had no 
impact on the MKP3 expression levels, a finding that excludes the PKC pathway as a 
regulator of MKPs. Yet, being important regulators of MAPK activity, it will be of 
interest to investigate the roles of MKPs in melanoma cell lines and tissue.  
 
NUR77 is a nuclear orphan receptor that is able to activate transcription independently 
of an exogenous ligand, and controls both apoptosis and survival in cancer cells, 
depending on its subcellular localization (218). NUR77 has been shown to be regulated 
by RSK, a down-stream substrate of ERK1/2 (219). Moreover, export of NUR77 from 
the nucleus, where it functions as an oncogenic survival factor,  to the cytoplasm, where 
it interacts with Bcl-2 and trigger apoptosis, has been shown to be regulated by JNK 
(220). Our microarray data showed that PD98059-treated spheroids have a 2.6 fold 
decrease in the NUR77 expression compared to the spheroid control, supporting MAPK 
regulation of NUR77. Interestingly, PMA treated spheroids showed a 3.4 fold increase 
in NUR77 expression compared to the control spheroids, an increase which was 
sustained also when the spheroids were treated with PD98059 and PMA in combination. 
It will be of interest to reveal a potential association between NUR77 and both 
PMA/PKC activation and the JNK pathway in melanoma cells. 
 
As mentioned in chapter 9.5, recent research has shown that increased Src activity 
protects lung adenocarcinoma and colon cancer cells from suspension-induced cell death 
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(anoikis). We have initiated studies in order to elucidate the role of Src in melanoma, 
hoping for an association with PMA mediated, anchorage-independent survival of 
melanoma cells. However, our results so far show no tendency in that direction. 
Nevertheless, our results are not less interesting. During our preliminarily investigation 
we inhibited Src activity using a specific inhibitor, PP2. We found that PP2, similarly to 
PMA, promoted cell survival, increased levels of the cyclins A and D1 and enhanced 
phosphorylation and thereby inactivation of the pro-apoptotic proteins Bim and Bad. 
These results were supported by proliferation assay (MTS) and flow cytometric analysis 
showing increased proliferation and survival, respectively, for PP2-treated spheroids. 
Several studies show that Src can regulate ERK1/2 activation. To study whether Src 
activation influenced any of the MAPK pathways in our cells or vice versa, spheroids 
were treated with PP2 as well as inhibitors of MEK, p38 and JNK. Inhibition of Src 
promoted sustained phosphorylation of ERK1/2 and JNK, but decreased phosporylation 
of p38 under anchorage-deprived conditions. However, inhibition of both the ERK1/2, 
p38 and JNK pathways induced a decrease in Src phosphorylation. So far, our results 
suggest that inactivation of Src promotes better cell survival in WM35 melanoma cells 
and that Src might be regulated by the MAPKs rather than vice versa. Our further aim is 
to transfect WM35 cells with siRNA directly targeting Src to investigate whether the 
better cell survival is due to PP2 mediated specific inhibition of Src or not. Moreover, 
we wish to characterize the upstream and downstream activators of Src in an attempt to 
elucidate the role of Src in melanoma cell signalling. 
 
JNK has also been connected to anchorage-independent growth. In this regard, it has 
been reported that mouse embryo fibroblasts lacking the JNK1/2 genes showed reduced 
anoikis resistance (221). Moreover, transfecting lung cancer cells with antisense 
oligonucleotides against JNK inhibited EGF-stimulated cell proliferation and anchorage-
independent growth (222). To follow the possible link between JNK and PKC-induced, 
MEK-independent ERK1/2 activation (paper II and III), it would be interesting to study 
whether JNK plays a role in anoikis resistance in melanoma cells and to further examine 
the regulation of JNK activity in these cells. 
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